Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Jul 12, 2019 at 9:50 AM EDT

What’s So Great About Hookipa Pharma’s HPV Cancer Treatment

Hookipa Pharma is not a household name, or even well-known within the biotech industry, but it is making waves on…

Chris Lange | Jul 11, 2019 at 9:50 AM EDT

Short Sellers Run for Cover From Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The June 28 short interest data…

Chris Lange | Jul 11, 2019 at 9:45 AM EDT

Big Pharma Sees Rising Tide in Short Interest

The June 28 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Jul 10, 2019 at 2:50 PM EDT

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated…

Jon C. Ogg | Jul 9, 2019 at 4:45 PM EDT

Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out

President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the…

Chris Lange | Jul 9, 2019 at 1:35 PM EDT

How Microsoft Plans to Innovate the Hospital of the Future

Microsoft announced that it is working with Providence St. Joseph Health, a U.S. hospital chain, in an effort to build…

Paul Ausick | Jul 9, 2019 at 11:55 AM EDT

What the Judge Did and Didn’t Say in the Drug Price Ruling

A federal District Court judge on Tuesday ruled that the U.S. Department of Health and Human Services could not force…

Chris Lange | Jul 8, 2019 at 3:49 PM EDT

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated…

Chris Lange | Jul 8, 2019 at 9:15 AM EDT

Why Intra-Cellular Therapies’ Depression Study Is Nothing to Smile About

Intra-Cellular Therapies has announced top-line results from its two late-stage trial in patients with bipolar depression.

Chris Lange | Jul 2, 2019 at 10:20 AM EDT

Tuesday’s Biggest Biotech Movers

24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each…

Chris Lange | Jul 1, 2019 at 10:00 AM EDT

How Pfizer Is Looking to Expand Its Eczema Treatment

Pfizer shares were up slightly on Monday after the firm announced topline results from its most recent late-stage study in…

Chris Lange | Jun 29, 2019 at 8:50 AM EDT

Pfizer’s Duchenne Muscular Dystrophy Pain Could Make Sarepta the DMD King

Pfizer released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy. While these results did…

Jon C. Ogg | Jun 28, 2019 at 12:15 PM EDT

Why Avid Bioservices Stock Could Still Double, Maybe

Avid Bioservices beat expectations around earnings, and it is adding customers and growing its backlog. One analyst has just reversed…

Chris Lange | Jun 27, 2019 at 12:20 PM EDT

Adaptive Biotechnologies Enters the Market With a Bang

Adaptive Biotechnologies entered the market with a bang on Thursday, well above the high end of the expected price range.

Paul Ausick | Jun 27, 2019 at 10:55 AM EDT

Why Centerbridge Would Buy Magellan Health — and Keep It

Private equity firm Centerbridge Partners is reportedly discussing an acquisition of health care provider Magellan Health. While not on the…

1 … 93 94 95 96 97 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

What’s So Great About Hookipa Pharma’s HPV Cancer Treatment

Short Sellers Run for Cover From Major Biotechs

Big Pharma Sees Rising Tide in Short Interest

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out

How Microsoft Plans to Innovate the Hospital of the Future

What the Judge Did and Didn’t Say in the Drug Price Ruling

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

Why Intra-Cellular Therapies’ Depression Study Is Nothing to Smile About

Tuesday’s Biggest Biotech Movers

How Pfizer Is Looking to Expand Its Eczema Treatment

Pfizer’s Duchenne Muscular Dystrophy Pain Could Make Sarepta the DMD King

Why Avid Bioservices Stock Could Still Double, Maybe

Adaptive Biotechnologies Enters the Market With a Bang

Why Centerbridge Would Buy Magellan Health — and Keep It

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

XRP vs Solana vs Ethereum: Which Altcoin is the Best Buy for Upside Right Now?

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

Health and Healthcare Articles

All Health and Healthcare Articles

What’s So Great About Hookipa Pharma’s HPV Cancer Treatment

Short Sellers Run for Cover From Major Biotechs

Big Pharma Sees Rising Tide in Short Interest

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out

How Microsoft Plans to Innovate the Hospital of the Future

What the Judge Did and Didn’t Say in the Drug Price Ruling

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

Why Intra-Cellular Therapies’ Depression Study Is Nothing to Smile About

Tuesday’s Biggest Biotech Movers

How Pfizer Is Looking to Expand Its Eczema Treatment

Pfizer’s Duchenne Muscular Dystrophy Pain Could Make Sarepta the DMD King

Why Avid Bioservices Stock Could Still Double, Maybe

Adaptive Biotechnologies Enters the Market With a Bang

Why Centerbridge Would Buy Magellan Health — and Keep It

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

XRP vs Solana vs Ethereum: Which Altcoin is the Best Buy for Upside Right Now?

Featured Reads

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up